Piper Jaffray Reiterates a Buy Rating on Voyager Therapeutics IncBy Austin Angelo
In a report issued on November 10, Joshua Schimmer from Piper Jaffray reiterated a Buy rating on Voyager Therapeutics Inc (NASDAQ: VYGR), with a price target of $37. The company’s shares closed last Friday at $12.24.
According to TipRanks.com, Schimmer is ranked 0 out of 5 stars with an average return of -3.7% and a 43.5% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Bellicum Pharmaceuticals, and Alexion Pharmaceuticals.
Voyager Therapeutics Inc has an analyst consensus of Moderate Buy.
Based on Voyager Therapeutics Inc’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $3.31 million and GAAP net loss of $9 million. In comparison, last year the company earned revenue of $4.94 million and had a GAAP net loss of $3.92 million.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops gene therapies for fatal and debilitating diseases of the central nervous system. The company focuses in the field of adeno-associated virus gene therapy through innovation and investment in vector optimization and engineering, and dosing techniques, as well as process development and production. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.